Description
Tizma (Tirzepatide) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, a once-weekly subcutaneous injectable twincretin that simultaneously activates the GIP receptor (GIPR) with potency comparable to native GIP and the GLP-1 receptor (GLP-1R) to potentiate glucose-dependent insulin secretion from pancreatic beta cells, suppress inappropriate glucagon release from pancreatic alpha cells, slow gastric emptying to attenuate postprandial glucose excursions, and engage central satiety circuits in the hypothalamus, producing clinically meaningful reductions in both HbA1c and body weight that exceed those of any previously approved incretin-based agent.
Supplied as a subcutaneous injection in a pre-filled syringe, 1 pre-filled syringe per box, available across the complete approved six-step strength range of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg, and manufactured by Globe Biotech Limited, Bangladesh. Its active ingredient, tirzepatide INN, is a 39-amino acid acylated peptide with structural homology to native GIP, engineered to bind and activate both GIPR and GLP-1R within a single molecular entity the first approved dual incretin receptor agonist (twincretin) in the antidiabetic drug class, structurally and mechanistically distinct from monoagonist GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide, exenatide) that activate only the GLP-1 receptor.
The co-activation of GIPR by tirzepatide augments the GLP-1R-mediated glycemic and weight effects by engaging adipose tissue GIP receptors involved in lipid partitioning and by potentiating pancreatic beta cell responsiveness through synergistic cyclic adenosine monophosphate (cAMP) signaling from both receptor pathways simultaneously. In the pivotal SURPASS-1 monotherapy trial (478 patients, 40 weeks), tirzepatide 5 mg achieved a mean HbA1c reduction of 1.87% from baseline versus 0.04% with placebo, with 87.4% of patients achieving HbA1c below 7.0% versus 19.9% with placebo, without hypoglycemia as monotherapy; tirzepatide at the 10 mg, 12.5 mg, and 15 mg escalation steps available in Tizma delivers progressively greater HbA1c and body weight reductions for patients requiring deeper glycemic correction. In the SURPASS-2 head-to-head trial versus semaglutide 1 mg (1,879 patients, 40 weeks), tirzepatide 15 mg achieved 2.37% mean HbA1c reduction and 11.2 kg mean body weight reduction versus 1.86% and 5.7 kg with semaglutide 1 mg (p<0.001), establishing tirzepatide at its maximum approved dose as the most efficacious approved injectable antidiabetic agent in any prospective randomized active-controlled trial.
Tizma by Globe Biotech Limited is the only Globe Biotech tirzepatide product supplying all six approved dose steps from the 2.5 mg tolerability initiation through the 15 mg maximum dose within a single, continuously sourced product range. Searching for Tizma Tirzepatide? Mediaid Pharmacy lists this product across its diabetes medicines and Tirzepatide Medicines portfolios and ships it worldwide.
Basic Product Information of Tizma (Tirzepatide)
| Brand Name | Tizma (Tirzepatide) |
| Product Name | Tizma |
| Generic Name | Tirzepatide INN |
| Drug Class | Dual GIP/GLP-1 Receptor Agonist; Twincretin; Glucose-Dependent Insulinotropic Polypeptide (GIP) Receptor Agonist; Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist; Dual Incretin Receptor Agonist; Once-Weekly Subcutaneous Injectable Antidiabetic Agent; Incretin Mimetic; Glucose-Dependent Insulin Secretion Potentiator; Glucagon Suppressor; Cardiometabolic Agent; Antiobesity Agent (Adjunct in T2DM) |
| Formulation | Subcutaneous Injection (Pre-filled Syringe) |
| Available Strengths | 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg tirzepatide per pre-filled syringe the full six-strength approved escalation range in a single Globe Biotech Limited product |
| Available Pack Size | 1 pre-filled syringe per box |
| Recommended Dose & Administration | Initiation dose (Weeks 1–4): 2.5 mg subcutaneously once weekly for 4 weeks. This is a tolerability initiation dose, not the therapeutic maintenance dose; it minimizes nausea and gastrointestinal adverse effects during treatment commencement. Step 1 First Therapeutic Dose: Increase to 5 mg subcutaneously once weekly after 4 weeks at 2.5 mg; maintain for at least 4 weeks before considering further escalation. Step 2: If additional glycemic control is required and 5 mg is tolerated, increase to 7.5 mg subcutaneously once weekly for at least 4 weeks. Step 3: If further intensification is required, increase to 10 mg subcutaneously once weekly for at least 4 weeks. Step 4: If additional control is still needed, increase to 12.5 mg subcutaneously once weekly for at least 4 weeks. Step 5 Maximum Approved Dose: 15 mg subcutaneously once weekly. The 15 mg strength is the maximum approved tirzepatide dose; all six strengths are available in the Tizma range from Globe Biotech Limited. Injection sites: Administer subcutaneously into the abdomen (at least 5 cm from the navel), thigh, or upper arm; rotate injection sites with each weekly dose to reduce local injection site reactions. Tizma may be injected at any time of day, with or without food. Missed dose: If a dose is missed and the next scheduled dose is more than 4 days away, administer the missed dose as soon as possible and resume the regular weekly schedule. If the next scheduled dose is 4 days or fewer away, skip the missed dose and continue with the next scheduled weekly injection. Do not administer two doses within 3 days of each other. Renal and hepatic impairment: No dose adjustment is required for mild to moderate renal impairment (eGFR 30 mL/min/1.73 m² or greater); use with caution in severe renal impairment. No dose adjustment required for hepatic impairment. Always confirm the dose, injection technique, and escalation schedule with the prescribing endocrinologist before initiating or adjusting Tizma therapy. |
| Primary Indications | Type 2 Diabetes Mellitus (T2DM): As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, used as monotherapy or in combination with other antidiabetic agents (metformin, sulfonylurea, SGLT2 inhibitor) or basal insulin when existing therapy does not achieve adequate glycemic control. Tirzepatide is not indicated for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis. Each treatment decision must account for baseline HbA1c, body weight goals, cardiovascular risk, concomitant antidiabetic medications, renal function, and gastrointestinal tolerability. Always consult the full prescribing information and the treating endocrinologist or diabetologist before initiating or adjusting Tizma therapy. |
| Manufacturer | Globe Biotech Limited, Bangladesh |
| Country of Origin | Bangladesh |
| SKU | tirzepatide-tizma |
| Categories | Diabetes Medicines; Tirzepatide Medicines |
| Storage Conditions | Store refrigerated at 2°C to 8°C (36°F to 46°F). Do not freeze; discard Tizma pre-filled syringes that have been frozen. If necessary, each pre-filled syringe may be stored unrefrigerated at room temperature up to 30°C (86°F) for a maximum of 21 days. Protect from light and direct heat. Keep in the original packaging until use. Keep out of the reach of children. Do not use after the expiry date printed on the carton and pre-filled syringe label. |
| Registration | Bangladesh |
| Originator Reference Brand | Mounjaro® (tirzepatide injection, developed and marketed by Eli Lilly and Company; approved by the U.S. Food and Drug Administration on May 13, 2022, as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus). Mounjaro® contains tirzepatide INN as the active pharmaceutical ingredient in the same dual GIP/GLP-1 receptor agonist (twincretin) drug class. Tizma is manufactured by Globe Biotech Limited in Bangladesh and is supplied through Mediaid Pharmacy for international procurement across all six approved strengths from 2.5 mg through 15 mg. |
| Global Supplier | Mediaid Pharmacy, Worldwide Shipping Available |
How Tizma (Tirzepatide) Works: Dual GIP and GLP-1 Receptor Agonism and Twincretin Pharmacology in Type 2 Diabetes
Tirzepatide INN is a 39-amino acid acylated peptide that functions as a dual agonist at two distinct incretin hormone receptors: the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R). This dual receptor co-activation the first of its kind among approved antidiabetic agents is the pharmacological basis for the term “twincretin.” Tizma (Tirzepatide), manufactured by Globe Biotech Limited in Bangladesh, reconstitutes both functionally impaired incretin axes of the type 2 diabetic pancreas within a single once-weekly subcutaneous injection, an approach that no monoagonist GLP-1 receptor agonist (semaglutide, liraglutide, dulaglutide, exenatide) can replicate.
GLP-1 is secreted by intestinal L cells in the distal ileum and colon following nutrient ingestion; it stimulates glucose-dependent insulin secretion from pancreatic beta cells, suppresses glucagon secretion from pancreatic alpha cells, slows gastric emptying to attenuate postprandial glucose excursions, and activates hypothalamic and brainstem satiety circuits. GIP is secreted by K cells in the duodenum and proximal jejunum in response to fat and carbohydrate ingestion; it potentiates insulin secretion through a cAMP signaling pathway in beta cells distinct from the GLP-1R pathway, and engages adipose tissue GIPR-expressing cells involved in lipid partitioning and energy balance. In type 2 diabetes mellitus (T2DM), both incretin axes are functionally impaired: the GLP-1 response is severely attenuated while the residual GIP incretin response fails to produce a normal insulin secretory reaction in the insulin-resistant beta cell.
Tirzepatide’s co-receptor architecture directly corrects this dual incretin deficit by simultaneously reconstituting GIP and GLP-1 receptor signaling, an effect accessible at every dose step from the 2.5 mg initiation dose through the 15 mg maximum dose available in the Tizma range from Globe Biotech Limited.
The structural basis of tirzepatide’s dual receptor activity lies in a 39-amino acid sequence with N-terminal structural homology to native GIP, optimized through specific amino acid substitutions to achieve balanced GIPR and GLP-1R binding affinity, conjugated at lysine-26 to a C20 fatty diacid moiety via a gamma-glutamic acid-miniPEG linker. This conjugation provides albumin binding exceeding 99%, protecting the peptide from N-terminal DPP-4 degradation that inactivates endogenous GIP and GLP-1 within 1 to 2 minutes of portal entry, and extends the elimination half-life to approximately 5 days, supporting steady-state concentrations achieved by 4 weeks of once-weekly subcutaneous administration at any dose step in the Tizma escalation range.
Tirzepatide activates GIPR with potency approximately equivalent to native GIP and activates GLP-1R with approximately 5-fold lower potency than native GLP-1, yet the GLP-1R-driven pharmacological outcomes insulin secretion, glucagon suppression, gastric emptying delay, appetite reduction, and body weight loss equal or exceed those of GLP-1 monoagonists at any corresponding dose step in head-to-head prospective trials. The progressive efficacy gain visible across Tizma’s six dose steps is the clinical expression of dose-dependent receptor saturation, incremental satiety signaling amplification, and cumulative adipose tissue GIP receptor engagement that compounds with each weekly escalation step.
At the 15 mg maximum dose accessible through Tizma a strength not available in Bangladeshi tirzepatide products limited to 7.5 mg tirzepatide achieved a mean HbA1c reduction of 2.37% and 11.2 kg mean weight loss versus semaglutide 1 mg in SURPASS-2 (1,879 patients, 40 weeks, p<0.001). Pharmacokinetically, tirzepatide reaches peak plasma concentration (Tmax) approximately 8 to 72 hours post-injection, achieves steady-state by week 4 of once-weekly dosing regardless of which strength is administered, and is cleared primarily through proteolytic degradation of the peptide backbone and fatty acid beta-oxidation, with no dominant CYP450 metabolic pathway and no pharmacokinetically significant drug accumulation across the full dose range. For the complete range of diabetes medicines at Mediaid Pharmacy, browse the full portfolio for worldwide shipping.
Tizma (Tirzepatide): Indications, Dosing, and Key Safety Information
| Approved Indications | Type 2 Diabetes Mellitus (T2DM): Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Tizma (Tirzepatide) is used as monotherapy when other oral antidiabetic agents are not tolerated or are contraindicated, and as add-on combination therapy with metformin, sulfonylureas, SGLT2 inhibitors, or basal insulin when single-agent or existing combination therapy fails to achieve adequate HbA1c targets. Tirzepatide is not indicated for type 1 diabetes mellitus or diabetic ketoacidosis. The treating endocrinologist determines appropriate candidacy, dose titration schedule across all six Tizma strength steps, and combination regimen based on individual patient HbA1c targets, body weight goals, cardiovascular risk, renal function, and gastrointestinal tolerability profile. |
| Full Dosing Schedule | Weeks 1–4 (Initiation): 2.5 mg subcutaneously once weekly a tolerability initiation dose only, not the therapeutic maintenance dose. Weeks 5 onward Step 1: 5 mg subcutaneously once weekly for at least 4 weeks (first therapeutic maintenance dose). In SURPASS-1 monotherapy (40 weeks), 5 mg achieved 1.87% mean HbA1c reduction with 87.4% of patients reaching HbA1c below 7.0%. Step 2: 7.5 mg subcutaneously once weekly for at least 4 weeks, if additional glycemic control is needed. Step 3: 10 mg subcutaneously once weekly for at least 4 weeks. In SURPASS-2, 10 mg achieved 2.10% HbA1c reduction and 9.3 kg weight loss versus semaglutide 1 mg. Step 4: 12.5 mg subcutaneously once weekly for at least 4 weeks. Step 5 Maximum Approved Dose: 15 mg subcutaneously once weekly. In SURPASS-2, 15 mg achieved 2.37% HbA1c reduction and 11.2 kg body weight loss versus semaglutide 1 mg (p<0.001). All six strengths are available in Tizma from Globe Biotech Limited. Inject into the abdomen, thigh, or upper arm; rotate sites each week. Administer at any time of day, with or without meals. |
| Common Adverse Reactions | The most frequently reported adverse reactions with tirzepatide across the SURPASS Phase 3 program are gastrointestinal in nature: nausea (12 to 18% at 5 mg, increasing modestly at higher dose steps), diarrhea (12 to 17%), vomiting (5 to 11%), and constipation (6 to 11%), predominantly occurring during the initiation and escalation phases and typically transient. The 2.5 mg initiation phase built into the Tizma dosing schedule is specifically designed to reduce gastrointestinal adverse event frequency and severity before advancing to the 5 mg therapeutic dose, and the 4-week minimum interval at each escalation step allows progressive adaptation before each dose increase through the 7.5 mg, 10 mg, 12.5 mg, and 15 mg steps. Injection site reactions (erythema, pain, bruising) are reported in approximately 3 to 7% of patients; site rotation with each weekly injection minimizes incidence. Hypoglycemia does not occur with Tizma as monotherapy due to tirzepatide’s strictly glucose-dependent insulin secretion mechanism; hypoglycemia risk increases when Tizma is combined with a sulfonylurea or basal insulin, requiring dose reduction of those agents at initiation. Rare serious adverse reactions include acute pancreatitis (discontinue Tizma immediately if suspected), severe hypersensitivity reactions including anaphylaxis and angioedema, and acute gallbladder disease (cholelithiasis, cholecystitis). Tizma (Tirzepatide) carries a boxed warning for thyroid C-cell tumors based on rodent carcinogenicity data; it is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Always discuss the complete safety profile with the treating endocrinologist before initiating or continuing Tizma therapy. |
| Drug Interactions | Oral medications with narrow therapeutic index or requiring rapid absorption: Tirzepatide delays gastric emptying and may reduce peak plasma concentration (Cmax) and alter time to peak (Tmax) of concomitantly administered oral drugs. Exercise particular caution with narrow therapeutic index agents including warfarin, cyclosporine, and digoxin. Oral contraceptives: Gastric emptying delay at each Tizma dose initiation or escalation step may transiently reduce oral contraceptive peak concentrations; switch to non-oral contraception or use a barrier method for 4 weeks after starting Tizma and for 4 weeks after each of the five dose escalation steps. Warfarin and vitamin K antagonists: Monitor INR more frequently when initiating Tizma or advancing through each dose step. Insulin secretagogues and basal insulin: Co-administration with a sulfonylurea or basal insulin increases hypoglycemia risk; consider dose reduction of those agents when adding Tizma to existing antidiabetic therapy. Other GLP-1 receptor agonists: Do not combine Tizma (Tirzepatide) with another GLP-1 receptor agonist (semaglutide, liraglutide, dulaglutide, exenatide); concurrent use provides no additional proven glycemic benefit and amplifies gastrointestinal adverse effects. |
| Contraindications | Tizma (Tirzepatide) is contraindicated in: patients with a personal or family history of medullary thyroid carcinoma (MTC); patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2); patients with known serious hypersensitivity to tirzepatide or any component of the Tizma formulation (including anaphylaxis or angioedema). Tirzepatide is not indicated for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis. |
| Renal Impairment | No dose adjustment of Tizma (Tirzepatide) is required for mild to moderate renal impairment (eGFR 30 mL/min/1.73 m² or greater). Use with caution in severe renal impairment (eGFR below 30 mL/min/1.73 m²) due to limited clinical data; tirzepatide’s predominantly non-renal clearance means pharmacokinetic exposure is not substantially increased by renal impairment, but gastrointestinal adverse effects occurring across the dose escalation steps particularly nausea, vomiting, and diarrhea may precipitate dehydration and acute kidney injury in renally vulnerable patients, requiring closer monitoring, hydration counseling, and renal function assessment at each dose step. Consult the treating endocrinologist and nephrologist for individualized guidance in patients with advanced chronic kidney disease before initiating or advancing Tizma through the 10 mg, 12.5 mg, or 15 mg escalation steps. |
| Pregnancy & Lactation | Tizma (Tirzepatide) is not recommended during pregnancy. Tirzepatide caused adverse embryo-fetal developmental effects in animal reproductive toxicity studies at clinically relevant exposures; adequate and well-controlled human data during pregnancy are not available. Insulin remains the preferred antidiabetic agent during pregnancy for type 2 diabetes mellitus. Women of childbearing potential should use effective contraception throughout Tizma therapy; if pregnancy occurs or is planned, discontinue Tizma and transition to insulin therapy immediately under the guidance of the treating endocrinologist. Breastfeeding is not recommended during Tizma treatment, as it is unknown whether tirzepatide is excreted in human breast milk and the risk to the nursing infant cannot be excluded. |
Who Should Use Tizma (Tirzepatide)?
Tizma (Tirzepatide) is indicated for adults with type 2 diabetes mellitus requiring improved glycemic control as an adjunct to diet and exercise a patient population characterized by progressive beta cell secretory failure, blunted GIP and GLP-1 incretin responses, pathological postprandial glucagon excess, and frequently co-existing overweight or obesity, for whom a once-weekly twincretin administered across a six-step dose escalation schedule provides the highest documented HbA1c and body weight reductions available from any approved injectable antidiabetic class. The procurement advantage of Tizma over competing Bangladeshi tirzepatide products is absolute: the availability of all six approved strength steps 2.5 mg initiation through 15 mg maximum in a single Globe Biotech Limited product range means endocrinologists never need to change supplier, brand, or product formulation as patients advance through every prescribed dose step.
First, adults with type 2 diabetes presenting with high baseline HbA1c (above 8.5%) or requiring HbA1c reductions exceeding 1.5% to reach individual targets form the primary clinical population where the full Tizma dose escalation range is most directly relevant. The six-step escalation architecture from 5 mg through 15 mg allows incremental intensification each step providing additional HbA1c reduction documented in the SURPASS Phase 3 program without requiring a formulation or supplier switch at any point. In SURPASS-1 monotherapy (40 weeks, 478 patients), tirzepatide 5 mg, 10 mg, and 15 mg produced HbA1c reductions of 1.87%, 1.89%, and 2.07% respectively, with 87.4%, 91.9%, and 93.1% of patients reaching HbA1c below 7.0%.
Second, adults with type 2 diabetes for whom clinically significant weight loss is a concurrent therapeutic priority are optimally served by the higher Tizma dose steps: tirzepatide 15 mg in SURPASS-2 produced 11.2 kg mean body weight reduction, nearly double the 5.7 kg achieved with semaglutide 1 mg. This degree of weight reduction, associated with improvements in waist circumference, systolic blood pressure, triglycerides, and insulin sensitivity, is only accessible through the 15 mg maximum dose available in Tizma.
Third, adults already on GLP-1 monoagonist therapy (semaglutide, liraglutide) who have achieved suboptimal glycemic or weight outcomes benefit from tirzepatide’s additional GIPR co-agonism a receptor signaling arm that monoagonist GLP-1 agents cannot engage, providing mechanistically additive glycemic and weight-reducing pharmacology.
Fourth, adults with type 2 diabetes for whom hypoglycemia avoidance is a priority benefit from tirzepatide’s glucose-dependent insulin secretion mechanism, which produced no monotherapy hypoglycemia across all six dose steps studied in the SURPASS program. Endocrinology programs and diabetes specialist centers co-sourcing Tizma alongside other injectable antidiabetic agents can browse the Mediaid Pharmacy injectable diabetes medicines portfolio for the complete selection available for international delivery.
Global Supplier: Mediaid Pharmacy Worldwide Shipping for Tizma (Tirzepatide)
Mediaid Pharmacy is a Dhaka-based supplier of specialty diabetes, endocrinology, and metabolic medicines with worldwide shipping to patients, diabetes specialist centers, endocrinology clinics, hospital pharmacy departments, and international distributors across all regions. Tizma (Tirzepatide), manufactured by Globe Biotech Limited in Bangladesh, is supplied as a subcutaneous injection in pre-filled syringes across all six approved strengths 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg at 1 pre-filled syringe per box, with pricing quotations, per-strength stock confirmation, full product documentation, and end-to-end international delivery tracking for every order.
The complete six-strength Tizma range spanning the 2.5 mg tolerability initiation dose, the 5 mg and 7.5 mg early therapeutic steps, and the 10 mg, 12.5 mg, and 15 mg higher escalation doses where tirzepatide’s clinical superiority over semaglutide is most pronounced allows endocrinology departments and diabetes clinics to procure the entire approved tirzepatide escalation sequence for their patient panels from a single Globe Biotech Limited product through a single Mediaid Pharmacy procurement channel. The pre-filled syringe format of Tizma supports once-weekly self-administration with no dose measurement or device assembly required beyond the ready-to-use pre-filled unit, streamlining procurement logistics, pharmacy dispensing protocols, patient counseling, and injection technique instruction across all six dose steps for clinics and programs managing patients at varying stages of the tirzepatide escalation schedule.
Diabetes specialist centers, endocrinology programs, hospital pharmacy departments, international distributors, and individual patients seeking tirzepatide injection Bangladesh supply can contact the Mediaid Pharmacy team through WhatsApp, phone, or WeChat for all inquiries regarding Tizma Tirzepatide stock availability, per-strength pricing, and international delivery timelines and logistics. Procurement teams co-sourcing Tizma alongside other specialty diabetes or metabolic medicines can browse the complete buy diabetes medicines online catalog and the Globe Biotech medicines portfolio before requesting a consolidated quotation.
Why Choose Tizma (Tirzepatide) from Mediaid Pharmacy?
Tizma (Tirzepatide) delivers the highest clinically documented HbA1c and body weight reductions among all approved injectable antidiabetic agents, a distinction earned through the SURPASS Phase 3 clinical trial program, which established tirzepatide’s twincretin mechanism simultaneous GIP and GLP-1 receptor co-activation as producing superior glycemic and cardiometabolic outcomes versus the most efficacious competing monoagonist GLP-1 receptor agonist in a prospective, randomized, active-controlled head-to-head design. In SURPASS-2 (1,879 adults with T2DM, 40 weeks), tirzepatide at 5 mg, 10 mg, and 15 mg outperformed semaglutide 1 mg at every dose in both HbA1c reduction and body weight reduction (p<0.001), with tirzepatide 15 mg achieving 2.37% HbA1c reduction and 11.2 kg weight loss versus 1.86% and 5.7 kg with semaglutide a magnitude of superiority that is only clinically accessible through a tirzepatide product supplying the 15 mg maximum dose.
Tizma’s complete six-strength pre-filled syringe range from Globe Biotech Limited 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg is the primary structural procurement advantage that distinguishes Tizma from every competing Bangladeshi tirzepatide product supplying only the 2.5 mg through 7.5 mg lower escalation steps: endocrinologists treating patients who require the 10 mg, 12.5 mg, or 15 mg steps for adequate glycemic and weight control can source those doses from the same Tizma product and the same Mediaid Pharmacy procurement channel without any formulation switch, supplier change, or product discontinuity for the patient.
From a tolerability management perspective, Tizma’s six-step escalation architecture with a mandatory 4-week minimum at each strength before advancing allows the prescribing endocrinologist to pause escalation at any step where additional GI adaptation time is needed, and the 2.5 mg initiation step reduces treatment discontinuation due to early gastrointestinal adverse effects before any therapeutic dose is reached.
Hypoglycemia is absent as monotherapy across the full Tizma dose range, a pharmacological property of tirzepatide’s glucose-dependent insulin secretion mechanism that makes it safe to escalate through all six strength steps without introducing hypoglycemia risk beyond that present in standard diabetic care.
Once-weekly subcutaneous dosing across a pre-filled syringe formulation requiring no assembly or measurement eliminates the daily injection burden of liraglutide and the daily oral adherence requirements of DPP-4 inhibitors and SGLT2 inhibitors across a patient panel that spans the full escalation spectrum. To source the full range of Globe Biotech Limited medicines and the complete selection of tirzepatide injection products at Mediaid Pharmacy, browse both portfolios and contact the team for a personalized quotation.
Frequently Asked Questions About Tizma (Tirzepatide)
What is Tizma (Tirzepatide) used for?
Tizma (Tirzepatide) is a dual GIP and GLP-1 receptor agonist a twincretin used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Administered once weekly as a subcutaneous injection via pre-filled syringe, Tizma is used as monotherapy when metformin or other oral agents are not tolerated or are contraindicated, and as add-on combination therapy with metformin, sulfonylureas, SGLT2 inhibitors, or basal insulin when existing treatment fails to achieve adequate HbA1c control. Tizma (Tirzepatide) works by simultaneously activating the GIP receptor (GIPR) and the GLP-1 receptor (GLP-1R) within a single weekly injection, stimulating glucose-dependent insulin secretion, suppressing inappropriate glucagon release, slowing gastric emptying to reduce postprandial glucose excursions, and engaging hypothalamic satiety circuits to reduce appetite and body weight. The originator reference brand is Mounjaro® (Eli Lilly and Company, FDA-approved May 13, 2022). Tizma is manufactured by Globe Biotech Limited in Bangladesh and is available through Mediaid Pharmacy with worldwide shipping to patients, diabetes specialist centers, and endocrinology clinics globally.
What is the generic name of Tizma?
The generic name of Tizma is tirzepatide INN. Tizma is the brand name registered by Globe Biotech Limited for tirzepatide manufactured in Bangladesh. Tizma is formulated as a subcutaneous injection in pre-filled syringes, available in six strengths 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg supplied as 1 pre-filled syringe per box, supporting the complete approved once-weekly dosing schedule from the 2.5 mg tolerability initiation dose through escalation to the 15 mg maximum approved tirzepatide dose as directed by the treating endocrinologist. The originator reference brand is Mounjaro® (Eli Lilly and Company). Mediaid Pharmacy distributes Tizma globally with worldwide shipping to patients, diabetes centers, endocrinology clinics, and hospital pharmacy departments.
What is the difference between Tizma (Tirzepatide) and Mounjaro® (Tirzepatide)?
Tizma and Mounjaro® both contain tirzepatide INN as the active pharmaceutical ingredient and share the same dual GIP/GLP-1 receptor agonist (twincretin) mechanism of action, the same once-weekly subcutaneous injection dosing schedule, and the same approved indication for type 2 diabetes mellitus. Mounjaro® is the originator brand developed and marketed by Eli Lilly and Company, approved by the FDA on May 13, 2022. Tizma is manufactured by Globe Biotech Limited in Bangladesh across the complete six-strength range 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg pre-filled syringes covering every approved tirzepatide dose escalation step, with 1 pre-filled syringe per box, available through Mediaid Pharmacy for international procurement by specialist diabetes centers, endocrinology clinics, hospital pharmacies, and individual patients in regions where Mounjaro® may be unavailable or cost-prohibitive. For the full range of buy tirzepatide injection online at Mediaid Pharmacy, browse the complete collection.
What are the available strengths of Tizma Tirzepatide?
Tizma (Tirzepatide) manufactured by Globe Biotech Limited is available in six strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg pre-filled syringes, supplied as 1 pre-filled syringe per box. The 2.5 mg strength is the 4-week tolerability initiation dose. The 5 mg is the first therapeutic maintenance dose. The 7.5 mg is step 2. The 10 mg and 12.5 mg are steps 3 and 4. The 15 mg is the fifth escalation step and the maximum approved tirzepatide dose. This complete six-strength range is the defining supply-chain advantage of Tizma over competing Bangladeshi tirzepatide products that supply only the lower 2.5 mg to 7.5 mg steps. For ordering, stock availability by strength, and current pricing, contact Mediaid Pharmacy at +8801773428128 or email info@mediaidpharmacy.com.
How is Tizma (Tirzepatide) administered?
Tizma (Tirzepatide) is administered once weekly as a subcutaneous injection using the pre-filled syringe. Recommended injection sites are the abdomen (at least 5 cm from the navel), the thigh, or the upper arm; rotate injection sites with each weekly administration to minimize local reactions. Tizma may be administered at any time of day, independently of meals. Begin with 2.5 mg once weekly for 4 weeks (tolerability initiation), then advance to 5 mg once weekly for at least 4 weeks. Continue escalation through 7.5 mg, 10 mg, 12.5 mg, and up to 15 mg once weekly each step maintained for a minimum of 4 weeks only if the treating endocrinologist determines that further glycemic intensification is required and the patient tolerates the current dose. Store Tizma pre-filled syringes refrigerated at 2°C to 8°C until use, or at room temperature up to 30°C for a maximum of 21 days when refrigeration is temporarily unavailable. Always confirm injection technique and each dose escalation step with the prescribing endocrinologist before commencing or advancing Tizma therapy.
What are the side effects of Tizma (Tirzepatide)?
The most common side effects of Tizma (Tirzepatide) are gastrointestinal: nausea (12 to 18% at 5 mg), diarrhea (12 to 17%), vomiting (5 to 11%), and constipation (6 to 11%), predominantly occurring during dose initiation and escalation and generally transient. The 2.5 mg initiation dose protocol built into the Tizma schedule specifically reduces early gastrointestinal adverse effects before advancing to the 5 mg therapeutic dose, and the 4-week minimum at each escalation step allows progressive adaptation through the 7.5 mg, 10 mg, 12.5 mg, and 15 mg dose steps. Injection site reactions (erythema, bruising, pain) are reported in approximately 3 to 7% of patients; site rotation at each weekly injection reduces incidence. Hypoglycemia does not occur with Tizma as monotherapy; risk increases when combined with a sulfonylurea or basal insulin. Rare but serious adverse reactions include acute pancreatitis (discontinue Tizma immediately if suspected), anaphylaxis, angioedema, and acute gallbladder disease. Tizma carries a boxed warning for thyroid C-cell tumors. Always review the complete safety profile with the treating endocrinologist before and during Tizma therapy.
Does Tizma (Tirzepatide) cause weight loss?
Yes. Tizma (Tirzepatide) produces dose-dependent, clinically meaningful body weight reductions in adults with type 2 diabetes, driven by dual GIP and GLP-1 receptor co-activation engaging hypothalamic satiety circuits, gastric emptying delay reducing caloric absorption rate, and adipose tissue GIPR modulation of energy partitioning. In SURPASS-1 monotherapy (40 weeks), tirzepatide 5 mg, 10 mg, and 15 mg produced mean body weight reductions of 7.0 kg, 7.8 kg, and 9.5 kg respectively versus 0.7 kg with placebo. In SURPASS-2 versus semaglutide 1 mg (40 weeks, 1,879 patients), tirzepatide 5 mg, 10 mg, and 15 mg produced weight reductions of 7.6 kg, 9.3 kg, and 11.2 kg all significantly greater than semaglutide 1 mg at 5.7 kg (p<0.001). The 11.2 kg weight loss at 15 mg, the maximum dose available in Tizma, represents a clinically transformative cardiometabolic improvement that is inaccessible through Bangladeshi tirzepatide products limited to 7.5 mg. For the full range of diabetes medicines at Mediaid Pharmacy available with worldwide shipping, browse the complete portfolio.
How does Tizma (Tirzepatide) compare to semaglutide for type 2 diabetes?
Tizma (Tirzepatide) and semaglutide (originator brand: Ozempic®) are both once-weekly subcutaneous injectable antidiabetic agents but operate through fundamentally different receptor mechanisms. Semaglutide is a GLP-1R monoagonist activating only the GLP-1 receptor. Tirzepatide is a dual GIP/GLP-1 receptor agonist (twincretin) co-activating both the GIPR and GLP-1R simultaneously adding an incretin signaling arm that semaglutide cannot engage. In SURPASS-2 (1,879 adults, 40 weeks), tirzepatide 5 mg, 10 mg, and 15 mg outperformed semaglutide 1 mg in HbA1c reduction (1.94%, 2.10%, 2.37% vs 1.86%) and body weight reduction (7.6 kg, 9.3 kg, 11.2 kg vs 5.7 kg) statistically significant at all dose levels (p<0.001 for both endpoints). Tizma’s ability to supply all six dose steps, including the 10 mg, 12.5 mg, and 15 mg steps where tirzepatide’s superiority over semaglutide is most pronounced clinically, is the key product differentiation for endocrinologists choosing between Bangladeshi tirzepatide formulations. The full selection of tirzepatide medicines at Mediaid Pharmacy is available for worldwide shipping; contact the team for per-strength pricing and current stock availability.
Can I order Tizma (Tirzepatide) online with worldwide shipping?
Yes. Mediaid Pharmacy supplies Globe Biotech Limited Tizma (Tirzepatide) pre-filled syringes, available in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg strengths, to patients, diabetes specialist centers, endocrinology clinics, hospital pharmacy departments, and healthcare providers globally. Contact Mediaid Pharmacy via WhatsApp, phone, or WeChat at +8801773428128, or email info@mediaidpharmacy.com for per-strength pricing, current stock availability, and international delivery details for your country.
Order Tizma (Tirzepatide) with Worldwide Shipping
Phone / WhatsApp / WeChat: +8801773428128 | Email: info@mediaidpharmacy.com




Reviews
There are no reviews yet.